-




Fig. 1 Anti-PT Results




Fig. 2 Anti-FHA Results





Fig. 3 Anti-PRN Results



Pre-and Post-Serum Antibody Responses Following Immunization With SB "Monovalent" Pa - AAPT, 1996 Anti-PT Results Fig.4





Fig. 5 Anti-FHA Results Pre-and Post-Serum Antibody Responses (Cont.) AAPT, 1996



Pre-and Post-Serum Antibody Responses (Cont.) AAPT, 1996

## 7/10

| Pain     | dtpa | dT  |
|----------|------|-----|
| ≤ 48 h   | 58   | 60  |
| 15 days  | 60   | 60  |
| Severe   | 0    | 0   |
| Redness  |      |     |
| ≤ 48 h   | 30   | 37  |
| 15 days  | 30   | 37  |
| > 20 MM  | 17   | 20  |
| Swelling |      |     |
| ≤ 48 h   | 30   | 37  |
| 15 days  | 30   | 37  |
| > 20MM   | 5    | 8.3 |
| Fever    |      |     |
| ≤ 48 h   | 7    | 7   |
| 15 days  | 8    | 8   |
| > 39°C   | 0    | 0   |

Fig. 7 % Reporting dtpa 005 - Reactogenicity

| Anti-D | dtpa | dΤ   |
|--------|------|------|
| Pre    |      |      |
| ≥ 0.1  | 44%  | 44%  |
| Post   |      |      |
| ≥ 0.1  | 80%  | 78%  |
| GMT    | 0.85 | 0.81 |
|        |      |      |
| Anti-T |      |      |
| Pre    |      |      |
| ≥ 0.1  | 88%  | 88%  |
| Post   |      |      |
| ≥ 0.1  | 97%  | 100% |
| GMT    | 7.37 | 13.6 |
|        |      |      |

Fig. 8 dtpa 005 SUBSTITUTE SHEET (RULE 26)

Erythema Weeks 2-4

3

0

|       | Pain<br>Week1 | Moderate<br>Pain<br>Week 1 | Erythema<br>Week 1 | Pain<br>Weeks<br>2-4 |   |
|-------|---------------|----------------------------|--------------------|----------------------|---|
| B-Med |               | 10                         | 40                 | 47                   | r |

8/10

SB-Med (N=31) Placebo (N=31)

· No serious adverse events

3

· No severe pain

19

· 2 subjects with hives (days 1-4; days 18-22)

3

3

Fig. 9 % Reporting AAPT- Reactogenicity

| Pain     | dtpa | dT |
|----------|------|----|
| ≤ 48 h   | 69   | 70 |
| 15 days  | 69   | 70 |
| Severe   | 0    | 1  |
| Redness  |      |    |
| ≤ 48 h   | 12   | 20 |
| 15 days  | 12   | 20 |
| > 30 MM  | 1    | 9  |
| Swelling |      |    |
| ≤ 48 h   | 12   | 28 |
| 15 days  | 13   | 30 |
| > 30MM   | 7    | 15 |
| Fever    |      |    |
| ≤ 48 h   | 5    | 6  |
| 15 days  | 13   | 15 |
| > 39°C   | 0    | 1  |

Fig. 10 % Reporting dtpa 003 - Reactogenicity SUBSTITUTE SHEET (RULE 26)

9/10

| Anti-D | dtpa | dТ   |
|--------|------|------|
| Pre    |      |      |
| ≥ 0.1  | 72%  | 72%  |
| Post   |      |      |
| ≥ 0.1  | 100% | 100% |
| GMT    | 3.3  | 10.5 |
|        |      |      |
| Anti-T |      |      |
| Pre    |      |      |
| ≥ 0.1  | 94%  | 99%  |
| Post   |      |      |
| ≥ 0.1  | 100% | 100% |
| GMT    | 22.9 | 54.5 |

Fig. 11 Antibody responses dtpa 003




Fig. 12 Anti-PT Results SUBSTITUTE SHEET (RULE 26)




Fig. 13 Anti-FHA Results




Fig. 14 Anti-PRN Results SUBSTITUTE SHEET (RULE 26)